AU Patent

AU2017353588B2 — 9-aminomethyl minocycline compounds and use thereof in treating Community-Acquired Bacterial Pneumonia (CABP)

Assigned to Paratek Pharmaceuticals Inc · Expires 2022-07-14 · 4y expired

What this patent protects

The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl] -minocycline or a salt thereof, in either oral or IV doses or a combination of both.

USPTO Abstract

The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl] -minocycline or a salt thereof, in either oral or IV doses or a combination of both.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017353588B2
Jurisdiction
AU
Classification
—
Expires
2022-07-14
Drug substance claim
No
Drug product claim
No
Assignee
Paratek Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.